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Abstract. An analysis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
genomes collected from the patients worldwide has identified mutations in the virus that could
aid in drug and vaccine development. The researchers found that the virus’s genetic diversity in
most countries is similar to what it is globally, suggesting that it was introduced repeatedly by
many infected people in each country rather than by a “patient zero.” The genetic analysis
found 198 mutations that have occurred more than once. “Mutations in themselves are not a
bad thing it is nothing to suggest SARS-CoV-2 is mutating faster or slower than expected.
Several factors, including pharmacogenetics, it is possible to contribute to inter-individual
variability in drug response. However, till today little is known about the host genetics
interaction with infection and COVID-19 progression. To understand the role of host gene, we
review the current literature, aggregate readily available genetic resources, and provide some
updated analysis relevant to COVID-19 and associated phenotypes.

Keywords: SARS-CoV-2, gene information, genetic variability, gene expression, gene
polymorphism

1 Introduction
Inter-individual variability in drug disposition is major cause for lack of efficacy or
adverse reactions to pharmacological treatment in up to 50% of all patients, posing
big challenges for medical care and drug development. Post-market safety events
resulting in drug withdrawals, boxed warnings or safety communications affect 32%
of all novel therapeutics approved by FDA from 2001 to 2010, leading to substantial
economic losses for pharmaceutical industry [1].

Furthermore, epidemiological data from the US shows that adverse drug reactions
(ADRs) cause 8.25% and 19.2% increase of hospital stay length and death rate,
respectively, and severe ADRs are estimated to be the 4th-6th leading cause of death
[2]. It is estimated that 20–30% of these negative effects can be attributed to genetic
variations and more than 200 pharmacogenomic biomarkers have by now been
incorporated into pharmacogenetics labels that can provide clinically actionable
information regarding drug choice or dosing.
The absorption, distribution, metabolism, elimination (ADME) of most drugs are
complex and involve multiple enzymes and transporter systems. As a consequence, it
is likely that the effects of functional alteration in one ADME protein on drug
response phenotypes can be amplified or compensated if they coincide with functional
variation in another component involved in the disposition of the same drug [3].
Importantly, while such combinatorial pharmacogenetic effects are plausible, only
few examples have been presented to date, including additive effects of functional
CYP2D6 duplications and UGT2B7*2 genotype for codeine toxicity in breastfed
neonates [4] and the balance between active CYP2D6 and CYP2C19 alleles for
amitryptiline toxicity [5].
Transmission [6] of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) occurs primarily via respiratory droplets from face-to-face contact and, to a lesser
degree, via contaminated surfaces. Aerosol spread may occur, but the role of aerosol
spread in humans remains unclear. An estimated 48%to 62%of transmission may
occur via presymptomatic carriers.
Common symptoms [7] in hospitalized patients include fever (70%-90%), dry
cough (60%-86%), shortness of breath (53%- 80%), fatigue (38%), myalgias (15%44%), nausea/vomiting or diarrhea (15%-39%), headache, weakness (25%), and
rhinorrhea (7%). Anosmia or ageusia may be the sole presenting symptom in
approximately 3%of individuals with COVID-19.
Common laboratory abnormalities [8] among hospitalized patients include
lymphopenia (83%), elevated inflammatory markers (eg, erythrocyte sedimentation
rate, C-reactive protein, ferritin, tumor necrosis factor-α, IL-1, IL-6), and abnormal
coagulation parameters (e.g, prolonged prothrombin time, thrombocytopenia, elevated
D-dimer [46%of patients], low fibrinogen).
Common complications [7, 9, 10, 11, 12, 13] among hospitalized patients with
COVID-19 include pneumonia (75%); acute respiratory distress syndrome (15%);
acute liver injury, characterized by elevations in aspartate transaminase, alanine
transaminase, and bilirubin (19%); cardiac injury, including troponin elevation (7%17%), acute heart failure, dysrhythmias, andmyocarditis; prothrombotic coagulopathy
resulting in venous and arterial thromboembolic events (10%-25%); acute kidney
injury (9%); neurologic manifestations, including impaired consciousness (8%) and
acute cerebrovascular disease (3%); and shock (6%).
1.1

Drug and gene information

162 drugs with pharmacogenetic labels were obtained from FDA [14], CPIC [15]
and DPWG [16]. This list was complemented with 100 top selling drugs, resulting in
a total of 212 drugs for analysis. ADME fingerprints of all compounds were extracted
from DrugBank.
1.2 Pharmacogenetic data
Genetic variability data was obtained from Ingelman-Sundberg et al., 2018[17].
The minor allele frequencies (MAFs) of variations classified as functional were
aggregated and complemented with the functional variants CYP1A2*1C (rs2069514),
CYP1A2*1F (rs762551), CYP2C19*17 (rs12248560), CYP3A4*22 (rs35599367),
CYP3A5*3 (rs776746), CYP2B6*22 (rs34223104), CYP2C8*3 (rs10509681,
rs11572080), CYP2C9*3 (rs1057910), CYP2E1*2 (rs72559710) and UGT1A1*28
(rs8175347), which were not included in the analyses. Furthermore, rs11572078 in
CYP2C8 and rs2297595 in DPYD were removed as false-positive predictions.
Zhou and Volker 2020 [18] extracted ADME information from 212 drugs
encompassing 94 associated genes involved in drug disposition or toxicity. The
selected drugs were distributed across therapeutic areas with most compounds being
used in psychiatry (n = 40), oncology (n = 35) and cardiology (n = 28; Fig. 1). The
genes that were implicated in the disposition of most drugs were CYP3A4 (n = 141
drugs), ABCB1 (n = 94 drugs), CYP2D6 (n = 92 drugs) and CYP2C19 (n = 64
drugs).
In addition to gene family- or subfamily-wide interactions, Zhou, Volker 2020
[18] found highly specific interactions between individual gene pairs. For instance, of
94 ABCB1 substrates in our data set, 81 were also substrates of CYP3A4 (Fig. 2A).
Accordingly, drugs that were transported by ABCB1 were 19.7% more likely to be
also CYP3A4 substrates than expected by chance. Similarly, implication of CYP2D6
was a decent predictor of CYP1A2 and CYP3A4 metabolism with ΔP values of 0.14
and 0.13, respectively (Fig. 2B). Notably however, DPCYP3A4, CYP2D6
substantially lower than ΔPCYP3A4, ABCB1. Further notable associations were
found for SLCO1B1 that shared substantial overlap with ABCC2 (ΔP = 0.57) and
ABCB1 (ΔP = 0.43; Fig. 2C).
Finally, TPMT overlapped with NUDT15 (ΔP = 0.74), ABCC5 (ΔP = 0.72) and
SLC29A1 (ΔP = 0.72) but not with CYPs (ΔP < 0), UGTs (ΔP < 0) or SULTs (ΔP <
0; Fig. 3D) [18].
1.3 Gene expression of ACE2 and TMPRSS2 variants
Asselta et al., 2020 [22] found no significant evidence for ACE2; it is not sure if
ACE2 is associated with disease severity/sex bias in the Italian population, TMPRSS2
levels and genetic variants proved to be possible candidate disease modulators,
contributing to the observed epidemiological data among Italian patients.
Children account for less than 2% of identified cases of coronavirus disease 2019
(COVID-19) [20, 23]. It is hypothesized that the lower risk among children is due to
differential expression of angiotensin-converting enzyme 2 (ACE2) [21], the receptor
that severe acute respiratory syndrome coronavirus 2 (SARSCoV- 2) uses for host

entry. Dong et al., [21] investigated ACE2 gene expression in the nasal epithelium of
children and adults.
The results from this study show age-dependent expression of ACE2 in nasal
epithelium, the first point of contact for SARS-CoV-2 and the human body.
Covariate-adjusted models showed that the positive association between ACE2 gene
expression and age was independent of sex and asthma. Lower ACE2 expression in
children relative to adults may help explain why COVID-19 is less prevalent in
children [21]. A limitation of this study is that the sample did not include individuals
older than 60 years.
The analysis by Asselta et al., 2020 [22] suggests a role for TMPRSS2 variants and
expression levels in modulating COVID-19 severity, a hypothesis that fosters a rapid
experimental validation on large cohorts of patients with different clinical
manifestations.
1.4 Functional of CYP2D6 by assessing primaquine 5-hydroxylation
Cytochrome P450 (CYP) 2D6 is involved in the metabolism of approximately 25%
of clinically used drugs, including antidepressants, β-blockers, anticancer drugs,
opioid analgesics, and antimalarial drugs [23].
Multiplexed targeted genotyping and MLPA analysis of 427 African–American,
Asian, Caucasian, Hispanic and Ashkenazi Jewish individuals identified the
frequencies of 16 variant CYP2D6 alleles and the copy number of exons 1, 4, 6 and 3
downstream region. It is shown that CYP2D6 metabolized Hydroxychloroquine [24].
1.5 Function and polymorphism of CYP3A4 and CYP3A5
Among the four cytochrome P450 (CYP) 3A genes, the most expressed in the liver
are CYP3A4 and CYP3A5. Till today are reported eighty single nucleotide
polymorphysms (SNP) of CYP3A4/5 to the Human P450 Allele Nomeclature
Committee. CYP3A4 alleles with minimal function compared with wild type include
the CYP3A4*6 and CYP4*17. The alleles which have moderately decreased or
altered activity include: CYP3A4*2,*8,*11,*12,*13,*16, and *18. CYP3A5 alleles
with minimal function include the splice variants CYP3A5*3,*5,*6 and CYP3A5*10,
as well as the null allele CYP3A5*7. Alleles with moderately decreased catalytic
activity include CYP3A5*8 and CYP3A5*9. This report reviews the current progress
in the functional characterization of CYP3A4 and CYP3A5 SNPs and provides
genotyping tests for possible defective variants. A combination of genotyping tests for
defective CYP3A4/CYP3A5 haplotypes will be necessary to understand the variations
in the metabolism and clinical toxicity of a wide variety of clinical drugs, since these
two CYP proteins have overlapping substrate specificities [25].
1.6 Toll like receptor 7 (TLR7)
van der Made [26] and colleagues 2020 describe 2 independent families with rare
germline variants in an innate immune-sensing gene, toll-like receptor 7 (TLR7), that
lead to severe disease in males who inherit the mutated gene on a single copy of their
X chromosome. The study implicates TLR7 as a critical node in recognizing SARS-

CoV-2 and initiating an early immune response to clear the virus and prevent the
development of COVID-19.
The study by van der Made and colleagues 2020 implicates insufficient control of
viral replication via TLR7 and innate immune sensing as a driver of severe COVID19 in young, previously healthy males from 2 independent families. In the first
family, the index case was a male patient, age 32 years, with severe COVID-19
requiring mechanical ventilation in the intensive care unit (ICU). His 29-year-old
brother died of COVID-19. Whole-exome sequencing was performed in the index
case, leading to the discovery of a 4-nucleotide hemizygous deletion likely leading to
a predicted total loss of function of TLR7 by introducing a premature termination
codon (c.2129_2132del; p.[Gln710Argfs*18]).
The index case in the second family was a male patient, age 21 years, with severe
COVID-19 complicated by pulmonary embolisms requiring mechanical ventilation in
the ICU. His 23-year-old brother had severe COVID-19 and required ICU care.
Exome sequencing revealed a missense variant (c.2383G>T; p.[Val795Phe]), which
was predicted as deleterious in all in silico prediction tools.
In conclusion, the study by van der Made [26] and colleagues 2020 provides
evidence that rare mutations in TLR7 were associated with severe COVID-19 in
young males from 2 independent families. While rare mutations in TLR7 are unlikely
to be a major driver of severe disease in most individuals infected with SARS-CoV-2,
the genetic study begins to unravel the molecular underpinnings of COVID-19. As
additional genetic loci are identified, such data could lead to improved diagnostics
and therapeutics, including rational repurposing of existing anti-inflammatory
therapies in either early infection or late stage severe disease.
In the study by Caspar et al [27] a series of 4 young male patients with severe
COVID-19, rare putative loss-of-function variants of X-chromosomal TLR7 were
identified that were associated with impaired type I and II IFN responses. These
preliminary findings provide insights into the pathogenesis of COVID-19.
1.7 UGT1A1 gene UDP (glucuronosyltransferase family 1 member A1)
The UGT1A1 gene belongs to a family of genes that provide instructions for making
enzymes called UDP-glucuronosyltransferases. These enzymes perform a chemical
reaction called glucuronidation, in which a compound called glucuronic acid is
attached (conjugated) to one of a number of different substances.
The protein produced from the UGT1A1 gene, called the bilirubin uridine
diphosphateglucuronosyl transferase (bilirubin-UGT) enzyme; UGT1A1 is the only
enzyme that glucuronidates bilirubin, a substance produced when red blood cells are
broken down. UGT1A1 converts the toxic form of bilirubin (unconjugated bilirubin)
to its nontoxic form (conjugated bilirubin).
Chinese research group Yao et al., 2020 [28] has made research by, biochemical
indicators of liver, blood clotting mechanism, routine blood test, UGT1A1 * 28 gene
polymorphism and other data of 40 cases with COVID-19 admitted to the isolation
ward of Tangdu Hospital were retrospectively analyzed. They came to conclusion that
COVID-19 combined with liver function injury may be due to the slight elevation of
transaminase, mostly around the second week of the disease course. Severe patients

have a higher proportion of liver injury, and critical type is an independent risk factor
for liver injury.
1.8 VDR gene vitamin D receptor
The VDR gene is responsible for making a protein called vitamin D receptor (VDR),
which allows the body to respond to vitamin D. This vitamin can be acquired from
foods in the diet or made in the body with help from sunlight exposure. Vitamin D is
involved in maintaining the proper balance of several minerals in the body, such as
calcium and phosphate; both calcium and phosphate are essential for the normal
formation of bones and teeth. One of vitamin D's major roles is to control the
absorption of calcium and phosphate from the intestines into the bloodstream.
Vitamin D is also involved in several processes unrelated to bone and tooth
formation.
The VDR protein attaches (binds) to the active form of vitamin D, known as
calcitriol. This interaction allows VDR to partner with another protein called retinoid
X receptor (RXR).
Vitamin D is produced in the skin under the influence of UVB-light from the sun
or obtained via the diet by eating fatty fish, enriched dairy products or supplements.
Vitamin D is known to support a healthy bone and severe deficiency may lead to
osteomalacia or the rickets, which still occur in poor areas of the world. In addition,
vitamin D support key functions in many organs, including the brain, muscle and the
immune systems [29]. In fact, the vitamin D receptor (VDR) is expressed in most cell
types and may activate somewhere between 200-500 genes, many related to the
immune system [30].
Substantial evidence supports a link between vitamin D deficiency and COVID-19
severity but it is all indirect. Community-based placebo-controlled trials of vitamin D
supplementation may be difficult. Further evidence could come from study of
COVID-19 outcomes in large cohorts with information on prescribing data for
vitamin D supplementation or assay of serum unbound 25(OH) vitamin D levels.
Meanwhile vitamin D supplementation should be strongly advised for people likely to
be deficient [31].
Finally, the field of vitamin D and Covid-19 is very active and several trials are
under way. Thus, new data will come, which may change these conclusions.
However, in the meantime the conclusions above can be followed and we have
massive data to say that vitamin D at low doses (1000-2000 IU/day) are safe and not
harmful, which is in line with the historical proverb: primum non nocere (first, do no
harm) – but potentially we may prevent a number of ARIs and perhaps also Covid-19
[30].
1.9 APOE e4 Gene
The ApoE e4 genotype is associated with both dementia and delirium [32], with the
e4e4 (homozygous) genotype associated with a 14-fold increase in risk of

Alzheimer’s disease [33] compared to the common e3e3 genotype, in populations
with European ancestries. Kuo et al 2020 [32], therefore, aimed to test associations
between ApoE e4 alleles and COVID-19 severity, using the UKB data.
The ApoE e4e4 allele increases risks of severe COVID-19 infection, independent
of preexisting dementia, cardiovascular disease, and type-2 diabetes. ApoE e4 not
only affects lipoprotein function (and subsequent cardio-metabolic diseases) but also
moderates macrophage pro-/anti-inflammatory phenotypes [34]. The novel
coronavirus SARS-CoV-2 causing COVID-19 uses the ACE2 receptor for cell entry.
ACE2 is highly expressed in type II alveolar cells in the lungs, where ApoE is one of
the highly co-expressed genes [35]. Further investigation is needed to understand the
biological mechanisms linking ApoE genotypes to COVID-19 severity.

2. Discussion
We present a review and analysis of COVID-19 host genetics and related phenotypes.
At the beginning of the current outbreak of COVID-19 in January 2020, the
guidelines are adopted for treating patients infected with SARS-CoV-2 were
established based on the previous experience with the MERS outbreak, although
clinical outcomes still need to be evaluated [43, 44]. We hope that this paper will help
clinicians understand, prioritize and monitor the drugs being used until results of
clinical trials are available.
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Fig. 1. Overview of the genes and drug considered for analysis. Large column plot depicts
the number of drug associations per gene. In total n = 212 genes were considered. The inlet
shows the distribution of drugs across therapeutic areas.

Fig. 2. Examples of specific interactions between pharmacogenes. The difference (DP)
between the posterior probability that gene 2 is involved in the disposition of a drug under the
condition that gene 1 is involved compared to the unconditional probability for metabolism by
gene 1, defined as ΔP = P(gene2|gene1) _ P(gene2) is shown for gene1 as ABCB1 (A),
CYP2D6 (B), SLCO1B1 (C) and TPMT (D) and the respective most closely correlated genes.
Venn diagrams show the overlap of the number of drugs for the top hits for each respective
gene.

